Vitamin D and primary hyperparathyroidism (PHPT).

Area of Science:

• Endocrinology
• Metabolic Bone Disease

Background:

• Vitamin D deficiency is highly prevalent in primary hyperparathyroidism (PHPT), particularly among postmenopausal women.
• Vitamin D deficiency may exacerbate PHPT, leading to larger tumors, higher parathyroid hormone (PTH) levels, and more severe bone disease.
• Physicians hesitate to administer vitamin D to hypercalcemic PHPT patients due to safety concerns.

Purpose of the Study:

• To investigate the safety and efficacy of vitamin D supplementation in PHPT patients.
• To explore the potential link between persistent vitamin D deficiency and tertiary hyperparathyroidism.
• To re-evaluate reference ranges for serum PTH by excluding individuals with vitamin D insufficiency.

Main Methods:

• Review of existing literature on vitamin D and PHPT.
• Analysis of patient data regarding vitamin D supplementation and its effects on calcium, PTH, and tumor size.
• Statistical analysis to determine adjusted PTH reference ranges.

Main Results:

• Vitamin D supplementation is safe for PHPT patients with serum calcium < 3 mmol/L, showing no increase in serum or urinary calcium.
• Supplementation decreased serum PTH concentrations in these patients.
• Excluding vitamin D insufficient individuals from reference populations suggested a 25-30% lower upper normal limit for serum PTH.

Conclusions:

• Vitamin D supplementation is a safe and effective strategy for managing PHPT patients with mild hypercalcemia.
• Persistent vitamin D deficiency might contribute to the development of tertiary hyperparathyroidism.
• Revised PTH reference ranges are necessary, excluding individuals with vitamin D insufficiency, to accurately diagnose PHPT.